Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
Crossref DOI link: https://doi.org/10.1007/s13300-016-0195-6
Published Online: 2016-08-23
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Evans, Marc
Gundgaard, Jens
Hansen, Brian Bekker
Funding for this research was provided by:
Novo Nordisk
Text and Data Mining valid from 2016-08-23
Article History
Received: 14 June 2016
First Online: 23 August 2016